This webinar will provide an overview of how Bio-Techne’s Assay Services’ Team expertise in RNAscope technology is being utilized by Biopharma for the development of biomarkers and companion diagnostic assays to support their therapeutic programs. Advanced Cell Diagnostics’ RNAscopeTM in situ hybridization (ISH) platforms are widely utilized for high resolution tissue-based and cell-specific analysis of targets and biomarkers. The RNAscope ISH platform is clinically validated and enables quantitative expression analysis that has repeatedly been proven to better stratify treatment-responsive and non-responsive patients in therapeutic clinical trials compared to traditional methods such as IHC and qPCR. RNAscope is often more sensitive than IHC and provides cell-specific biomarker data in complex tissue microenvironments that qPCR cannot.
- Biomarker validation to accelerate translation of assays into clinical development in a GCLP setting in a matter of 4-6 weeks*
- Assay feasibility and development - sensitivity, specificity, and precision testing (repeatability & reproducibility)
- Development of pathologist scoring and HALOTM image analysis algorithms for biomarker assessment.
- Established protocols for clinical assay transfer to CLIA-certified labs for prospective use.
- RNAscope multiplexing and validated protocols for co-detection of biomarkers and immune cell markers
- Quantifiable, cell-specific, single-molecule detection of RNA biomarkers in tumor biopsies
- Superior performance against traditional methods, e.g., IHC, qPCR
- Application in small molecule, biologic, and cell therapy biomarkers
